The revenue of the company grew by 23% y-o-y to INR 10.29 bn almost in line with our estimates of INR 10.89 bn. The revenue growth was led by pharmaceutical segment (+46% y-o-y). On the raw material front, OPM fell by 78 bps y-o-y to 17.5% primarily on account of higher RMAT cost, however lower other cost restricted further stress on the operational performance. EBITDA grew by 18% y-o-y to INR 1.80 bn....